iSBTc 25th Annual Meeting
Hot Topic Symposium:
CTLA-4 Blockade as a Cancer Therapeutic: How Do We Build on a Successful Foundation?
10:30am - 12:00pm
October 4, 2010
Hyatt Regency Washington on Capitol Hill
Washington, D.C.
Symposium Chair
James P. Allison, PhD
Memorial Sloan-Kettering Cancer Center
This cutting-edge session will present exciting new data on CTLA-4 blockade, including existing therapeutic combinations with anti-CTLA-4 that are poised for clinical use, potential future combinations, and insights into future directions in CTLA-4 blockade research and clinical translation.
Program Goals
-
Present latest pre-clinical and clinical data on CTLA-4 blockade in combination with other therapeutic agents.
-
Explore future therapeutic combinations and clinical applications of CTLA-4 blockade for cancer treatment.
-
Review clinical trial designs and biomarker endpoints to advance clinical translation of CTLA-4 blockade for cancer treatment.
-
Explore directions for future research and application of CTLA-4 blockade in clinical oncology.
Intended Learner Outcomes
Upon completion of this meeting, participants will be able to:
-
Discuss the latest clinical data on CTLA-4 blockade for cancer treatment.
-
Identify promising therapeutic combinations with CTLA-4 blockade.
-
Apply new considerations for clinical trial design and biomarkers in studies of CTLA-4 blockade.
-
Identify productive new research directions to advance CTLA-4 blockade and improve cancer outcomes.
The Hot Topic Symposium is a non-accredited continuing medical education event. No credits are offered for physician participation in this educational program.